Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn’s New Phase 3 Study
The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
In the current psychedelics landscape, one of the most important topics is compound legality.
While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis.
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology.
Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
Psychedelics mental healthcare company Numinus Wellness Inc. (OTCQX: NUMIF) announced its financial results for the three and six months ended Feb. 28, 2023.
Q2 numbers show:
Total cash of $14.7 (CA$19.7) million as of Feb. 28, 2023.
Awakn’s Psychedelics Medical Chief Steps Down, Shifts In Company’s Stocks And Ownership
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate news.
EXCLUSIVE: Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga’s Psychedelics Capital Conference
At the second edition of Benzinga’s Psychedelics Capital Conference, held in sunny Miami, leaders from four major ketamine therapy companies shared their optimistic insights and guidance about the industry.